Commercialization of API Manufacturing Using a Continuous-Flow Process
First written in FY2023. 1 of 2 entries say "Advanced", first in FY2026. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Continuous-flow processing offers advantages in efficiency because the target compound can be extracted as raw materials are fed into linked reaction vessels, in operational safety because it reduces opportunities to come into contact with highly hazardous substances during manufacturing, and in environmental compatibility because it enables chemical synthesis in a compact footprint and reduces even the energy required to extract the target compound. To increase the number of products to which this process is applied, we will promote collaboration among industry, academia and government and with other segments within the group, while making the necessary capital investments in stages.」
The company specified initiatives to increase the number of products using continuous-flow processing through collaboration among industry, academia and government and with other segments, together with phased capital investment. - FY2023First statedAnnual report
「Going forward, we will work on manufacturing active pharmaceutical ingredients, including drugs for treating benign prostatic hyperplasia, using continuous-flow processing.」
The company outlined a policy of applying continuous-flow processing, which it considers superior to conventional synthesis methods in efficiency, safety and environmental compatibility, to the manufacture of active pharmaceutical ingredients for drugs treating benign prostatic hyperplasia and other products.